ライフサイエンスコーパス: lipoxygenase inhibitor

1 usly used to characterize cyclooxygenase and lipoxygenase inhibitors.

2 droxyl radicals, and most of them are potent lipoxygenase inhibitors.

3 dependent gene expression was inhibited by 5-lipoxygenase inhibitors.

4 rious agents were given in the presence of 5-lipoxygenase inhibitors.

5 ndpoints for future clinical trials of 12/15-lipoxygenase inhibitors.

6 rategies for future development of selective lipoxygenase inhibitors.

7 Lipoxygenase inhibitors 2,3,5-trimethyl-6-(12-hydroxy-5-

8 However, application of the lipoxygenase inhibitors 5,8,11-eicosatrienoic acid and n

9 ONO-RS-082, quinacrine and AACOCF3) and the lipoxygenase inhibitor AA861 delayed the initial outgrow

10 tor, nordihydroguaiaretic acid (NDGA), the 5-lipoxygenase inhibitor, AA861, the epoxygenase inhibitor

11 hacin was not blocked by the addition of a 5-lipoxygenase inhibitor, AA861.

12 Phospholipase A2 and lipoxygenase inhibitors also prevented acute neurite ret

13 discussed, including combination therapies, lipoxygenase inhibitors, and lasers.

14 ygenase inhibitors, the lack of benefit from lipoxygenase inhibitors, and possible future methodologi

15 However, 5-lipoxygenase inhibitors, anti-IgE, and immunomodulatory

16 hes such as NO-COX-2 inhibitors and dual COX-lipoxygenase inhibitors are already warranting interest.

17 Multiple structurally distinct lipoxygenase inhibitors as well as mouse DRG neurons lac

18 enzymes was examined in the presence of the lipoxygenase inhibitor baicalein and/or exogenous 12(S)H

19 4-aminopyridine (4-AP; 100 microM) and a 12-lipoxygenase inhibitor, baicalein (5 microM), suggesting

20 5-Lipoxygenase inhibitors blocked IL-16-, eotaxin-, and RA

21 bited by both nonspecific cyclooxygenase and lipoxygenase inhibitors but not by inhibitors specific f

22 We demonstrated that 5-lipoxygenase inhibitors, but not cyclooxygenase inhibito

23 The 12-lipoxygenase inhibitor, cinnamyl-3,4-dihydroxy-alpha-cya

24 ects these cells from apoptosis induced by 5-lipoxygenase inhibitors, confirming a critical role of 5

25 bition of lipoxygenases because other potent lipoxygenase inhibitors failed to activate bTREK-1.

26 Neither cyclooxygenase or lipoxygenase inhibitors had any effect on arachidonic ac

27 2+-pumping pools, whereas cyclooxygenase and lipoxygenase inhibitors had no effect.

28 This is the first study in which a 5-lipoxygenase inhibitor has been shown to attenuate exerc

29 Pharmacological intervention with lipoxygenase inhibitors may be an important new clinical

30 e cyclooxygenase inhibitor aspirin and the 5-lipoxygenase inhibitor MK-886 both partially inhibited D

31 ether inhibition of LT biosynthesis with a 5-lipoxygenase inhibitor (MK-591) induces remission in pat

32 Neither nordihydroguaiaretic acid (a lipoxygenase inhibitor) nor ethoxyresorufin (a cytochrom

33 The lipoxygenase inhibitor nordihydro-guaiaretic acid and th

34 Treatment with the lipoxygenase inhibitor nordihydroguaiaretic acid (10 mic

35 The lipoxygenase inhibitor nordihydroguaiaretic acid, the sp

36 In this study, we examined the effects of 5-lipoxygenase inhibitors (nordihydroguaiaretic acid and A

37 addition, MA-10 cells were treated with the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA)

38 s of superoxide-generating enzymes, only the lipoxygenase inhibitor, nordihydroguaiaretic acid reduce

39 rompted the development of a large number of lipoxygenase inhibitors of possible therapeutic and prob

40 mes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.

41 ombination with EGF, countered the effect of lipoxygenase inhibitors on PKC activation, and 12(S)HETE

42 Before initiating therapy with the 5-lipoxygenase inhibitor or placebo, only nine of 18 asthm

43 asthma received either 600 mg zileuton, a 5-lipoxygenase inhibitor, or a placebo four times daily fo

44 hibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileuton alone.

45 no bronchodilation after nine doses of the 5-lipoxygenase inhibitor (p=0.95).

46 Nordihydroguaiaretic acid, a lipoxygenase inhibitor, prevented A23187 and exogenous A

47 In addition, lipoxygenase inhibitors reduce phenylephrine-induced con

48 Lipoxygenase inhibitors reduced the wound-induced accumu

49 viorally in rats in vivo, NRM infusion of 12-lipoxygenase inhibitors significantly reduced DOR-induce

50 The addition of nordihydroguaiaretic acid, a lipoxygenase inhibitor, significantly increased NaBT-ind

51 ction observed in various settings following lipoxygenase inhibitor treatment.

52 scovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the dev

53 in-treated cells, whereas cyclooxygenase and lipoxygenase inhibitors were ineffective, indicating tha

54 Four different lipoxygenase inhibitors, which might be expected to lead

55 asthmatics and evaluate the effects of the 5-lipoxygenase inhibitor zileuton on these responses.

56 Treatment with the 5-lipoxygenase inhibitor zileuton reduced postantigen BALF

57 that were abrogated by anti-PlGF Ab or the 5-lipoxygenase inhibitor zileuton.

58 kast, zafirlukast, and pranlukast, and the 5-lipoxygenase inhibitor, zileuton, are unique in their ab